"Das Department für Frauengesundheit (Universitäts-Frauenklinik und Forschungsinstitut für Frauengesundheit) befasst sich mit der Erforschung, Erkennung, Vorbeugung und Heilung von spezifischen Erkrankungen von Frauen und betreibt eine umfangreiche Versorgung rund um das Gebiet von Schwangerschaft und Geburt und den gynäkologischen Erkrankungen. Es gehört zu den führenden Einrichtungen in Deutschland. Mit dem integrierten Forschungsinstitut für Frauengesundheit wird dieser umfassende Ansatz strukturell und inhaltlich noch zusätzlich ergänzt."

During the past decade, Universitätsklinik Tübingen; Frauenklinik conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 12 clinical trials were completed, i.e. on average, 92.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 5 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinik Tübingen; Frauenklinik" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "AGO Study Group" with 3 trials sponsored, "University Hospital Tuebingen" with 3 trials sponsored, "AGO Research GmbH" with 2 trials sponsored and "Ethicon, Inc." with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinik Tübingen; Frauenklinik" #1 collaborator was "Hoffmann-La Roche" with 3 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 2 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "German Breast Group" with 2 trials as a collaborator and "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator. Other collaborators include 26 different institutions and companies that were collaborators in the rest 36 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinik Tübingen; Frauenklinik" are "Breast Cancer" (8 trials), "Ovarian Cancer" (4 trials), "Metastatic Breast Cancer" (3 trials), "Breast Neoplasms" (2 trials) and "Triple Negative Breast Cancer" (2 trials). Many other conditions were trialed in "Universitätsklinik Tübingen; Frauenklinik" in a lesser frequency.

Most popular intervention types in "Universitätsklinik Tübingen; Frauenklinik" are "Drug" (26 trials), "Procedure" (3 trials), "Device" (1 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (5 trials), "Placebo" (5 trials), "Docetaxel" (4 trials), "Pertuzumab" (4 trials) and "Atezolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinik Tübingen; Frauenklinik" are 20 trials for "Female" genders and 13 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinik Tübingen; Frauenklinik". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Universitätsklinik Tübingen; Frauenklinik, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinik Tübingen; Frauenklinik, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".